Functional Proteins in Polycystic Ovary Syndrome

Last updated: January 31, 2025
Sponsor: Jagiellonian University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Polycystic Ovarian Syndrome

Reproductive Health

Treatment

Measurement of zonulin concentration

Measurement of ghrelin concentration

Measurement of kisspeptin concentration

Clinical Study ID

NCT06793098
1072.6120.44.2024-3
  • Ages 18-45
  • Female
  • Accepts Healthy Volunteers

Study Summary

The concentration of functional proteins: kisspeptin, ghrelin, zonulin will be measured and compared in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR), in women with PCOS without IR, and in women without PCOS.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • women aged 18-45 years

Exclusion

Exclusion Criteria:

  • removal of at least one ovary

  • treated diabetes of any type

  • diagnosed and treated metabolic diseases

  • diagnosed and treated autoimmune diseases

  • diagnosed and treated autoinflammatory diseases

Study Design

Total Participants: 100
Treatment Group(s): 3
Primary Treatment: Measurement of zonulin concentration
Phase:
Study Start date:
January 20, 2025
Estimated Completion Date:
December 31, 2026

Study Description

Polycystic Ovary Syndrome (PCOS) is currently the most common endocrine disorder in women of reproductive age with an unknown etiology. A predominant metabolic feature of PCOS is insulin resistance (IR), which contributes to the pathogenesis and expression of other symptoms of the syndrome, such as hyperandrogenism. The metabolic disturbances in women with PCOS result in a higher incidence of cardiovascular diseases and endometrial cancer in the premenopausal age. The gold standard for assessing peripheral tissue sensitivity to insulin is the hyperinsulinemic-euglycemic clamp technique; however, this method is not commonly used in clinical practice due to its complexities. Instead, simpler tests, such as the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and fasting insulin measurements along with glucose tolerance tests, are employed. These methods are utilized for diagnosing insulin resistance rather than identifying predispositions. Therefore, there is an urgent need to identify more precise markers of IR that could be used in routine early-stage assessments. Given the long-term complications associated with PCOS, which can shorten life expectancy, early diagnosis and treatment of IR are crucial. Furthermore, such studies may contribute to exploring the etiopathogenesis of the syndrome. The discovery of "markers" that can predict or diagnose metabolic abnormalities at an early stage, prior to the onset of clinical symptoms, would facilitate early intervention and treatment, thus preventing a decline in quality of life associated with PCOS.

This study will measure and compare the concentrations of locally acting hormones: ghrelin, kisspeptin, and zonulin in three research groups: women with polycystic ovary syndrome (PCOS) and insulin resistance (IR), women with PCOS without IR, and women without PCOS. Measurements will be performed using immunoenzymatic methods (ELISA) and the Erba XL biochemical analyzer. Statistical calculations will be conducted using SPSS Statistics software.

Connect with a study center

  • Jagiellonian University

    Krakow,
    Poland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.